Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889310 | 0.85 | HSD17B10 (0.39) | HSD17B10KDM4ELMNAALDH1A1HPGD | |
| SCHEMBL7618865 | 0.78 | SMN1; SMN2 (0.50) | HSD17B10KDM4EALDH1A1HPGDADORA3 | |
| SCHEMBL888691 | 0.77 | HSD17B10 (0.36) | HSD17B10KDM4ELMNAALDH1A1HPGD | |
| SCHEMBL12810051 | 0.77 | HSD17B10 (0.36) | HSD17B10KDM4ELMNAALDH1A1HPGD | |
| SCHEMBL18776144 | 0.76 | HSD17B10 (0.35) | HSD17B10KDM4ELMNAALDH1A1HPGD | |
| SCHEMBL3578263 | 0.74 | METAP2 (0.44) | HSD17B10KDM4ELMNAALDH1A1HPGD | |
| SCHEMBL10604271 | 0.74 | ADORA3 (0.57) | HSD17B10KDM4ELMNAALDH1A1HPGD | |
| SCHEMBL1551605 | 0.73 | NUDT1 (0.44) | HSD17B10KDM4ELMNAALDH1A1HPGD | |
| SCHEMBL7068568 | 0.73 | SMN1; SMN2 (0.42) | ADORA2AADORA1SMN1; SMN2 | |
| SCHEMBL1551964 | 0.73 | PDK2 (0.36) | KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8221737-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20110070196-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110064698-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20100316607-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316607-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | HSD17B10 581/4885KDM4E 1193/4885LMNA 2800/4885 |
| US-20110070196-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | HSD17B10 643/4885KDM4E 1139/4885LMNA 2791/4885 |
| US-20110064698-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | HSD17B10 643/4885KDM4E 1139/4885LMNA 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.